iBio, Inc. (IBIO) announced the results of its 2026 Annual Meeting of Stockholders, held on October 14, 2026. The meeting addressed several corporate governance matters, including the election of directors, the ratification of an independent auditor, and the approval of amendments to the company’s capital structure and incentive plans.
Shareholders elected two Class III directors to the Board of Directors. William Clark received 35,039,749 votes for, and Gary Sender received 35,909,610 votes for. Both nominees were elected to serve a three-year term expiring at the 2029 Annual Meeting.
The stockholders also ratified the appointment of Grassi & Co., CPAs, P.C. as the company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The ratification received 47,499,835 votes for, 140,624 votes against, and 603,805 abstentions.
On the advisory, non-binding say-on-pay proposal, the stockholders approved the compensation of the company’s named executive officers. The approval received 35,524,321 votes for, 404,426 votes against, and 254,765 abstentions.
Shareholders approved an amendment to the company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 275,000,000 shares to 500,000,000 shares. This increase was approved with 45,730,093 votes for, 2,052,563 votes against, and 461,608 abstentions. The amendment was filed with the Secretary of State of Delaware on October 16, 2026, and became effective upon filing.
Additionally, shareholders approved Amendment No. 1 to the iBio, Inc. 2023 Omnibus Incentive Plan. The amendment modifies the plan’s “evergreen” provision, which dictates how the number of shares reserved for issuance increases over time. Specifically, the amendment sets the following share reserve increases:
- January 1, 2027, 2028, and 2029: An increase equal to 5% of common stock outstanding on December 31 of the preceding year plus 3% of shares issuable upon exercise of pre-funded warrants outstanding on December 31 of the preceding year.
- January 1, 2030, 2031, 2032, and 2033: An increase equal to 5% of common stock outstanding on December 31 of the preceding year, subject to the Board of Directors potentially reducing this number prior to January 1 of the given year.
The Plan Amendment was approved with 27,693,575 votes for, 8,263,100 votes against, and 226,837 abstentions.
